.Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX21_Eplontersen.Eplontersen .Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX21_Eplontersen.Eplontersen| name: | Eplontersen |
| ATC code: | N07XX21 | route: | subcutaneous |
| n-compartments | 2 |
Eplontersen is an antisense oligonucleotide inhibitor of transthyretin (TTR) synthesis, aiming to reduce serum TTR protein levels. It is developed for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in adults. In 2023, Eplontersen (brand name Wainua) was granted FDA approval for this indication.
Pharmacokinetic parameters estimated for subcutaneous administration in adult patients; no peer-reviewed publication with detailed PK model found as of June 2024.